Skip to main content
. Author manuscript; available in PMC: 2023 Jul 4.
Published in final edited form as: Mol Pharm. 2022 Apr 29;19(7):2535–2541. doi: 10.1021/acs.molpharmaceut.2c00211

Figure 4.

Figure 4.

Comparison of uptake in tumor and kidneys between 64Cu-NOTA-PEG2Nle-CycMSHhex (PEG2Nle) and 64Cu-NOTA-GGNle-CycMSHhex (GGNle) at 2, 4 and 24 h post-injection. The data of 64Cu-NOTA-GGNle-CycMSHhex was cited from our previous publication (ref. 14) for comparison. *p<0.05